SRPX Human Pre-designed siRNA Set A

Cat. No.: S1467358

Storage

Store at -20°C

Shipped In

Ice chest + Ice pads

Panoramica

SRPX Human Pre-designed siRNA Set A contains three designed siRNAs for SRPX gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components SRPX siRNA-1: 5 nmol (HPLC) SRPX siRNA-2: 5 nmol (HPLC) SRPX siRNA-3: 5 nmol (HPLC) siRNA Negative Control: 5 nmol (HPLC) FAM-labeled siRNA Negative Control: 5 nmol (HPLC) GAPDH siRNA Positive Control:5 nmol (HPLC)

Specifications

Condizioni di conservazione di stoccaggio

Store at -20°C

Spedito in

Ice chest + Ice pads

Questo prodotto richiede spedizione a catena fredda. I servizi di terra e altri servizi economici non sono disponibili.

Product Line

Prodotti biologici

Application Protocols

No vendor-tested application data are provided for this item. The following outlines general, literature-based guidance for siRNA use; adapt and optimize for your system.

General workflow for siRNA transfection (adherent cells):

1. Plate cells to achieve ~50–70% confluence the next day.
2. Prepare two tubes:
   • Tube A: Dilute siRNA in serum-free, antibiotic-free medium to the desired working concentration (e.g., to achieve 5–50 nM final after addition to cells).
   • Tube B: Dilute transfection reagent in the same medium per manufacturer instructions.
3. Combine A and B; mix gently and incubate 5–20 min at room temperature to allow complex formation.
4. Replace culture medium with fresh complete medium or add complexes directly per reagent guidance; distribute complexes to wells.
5. Incubate cells under standard conditions. Assess mRNA knockdown at 24–48 h and protein knockdown at 48–96 h.
6. Include controls: non-targeting siRNA, mock transfection, and a positive-control siRNA.

Electroporation alternative:

• Use instrument-specific buffers and programs; deliver defined pmol siRNA per million cells as recommended by the device/reagent manufacturer.

These steps are general guidance only and are not validated for this specific product. Refer to your transfection reagent instructions and institutional SOPs.

Biological Roles

SRPX (Sushi Repeat Containing Protein, X-linked) encodes an extracellular matrix–associated protein characterized by multiple sushi (complement control protein, CCP) repeats. While specific biological roles can vary by context and cell type, literature suggests involvement in:

• Cell–matrix and cell–cell interactions: Sushi/CCP domains are common in proteins mediating extracellular interactions, potentially influencing adhesion and signaling.
• Secreted/extracellular localization: Many SRPX family members are secreted or membrane-associated, positioning them to modulate the pericellular environment.
• Tissue remodeling and morphogenesis: CCP-containing proteins frequently participate in matrix organization and protease regulation, which can affect tissue remodeling (general family-level insight).

Using this siRNA set enables experimental interrogation of SRPX function by reducing transcript levels and observing downstream molecular and phenotypic changes. Typical readouts include:

• Changes in transcript profiles (RT-qPCR/RNA-seq) of ECM and adhesion pathways after SRPX knockdown.
• Alterations in cell adhesion, migration, or morphology in in vitro assays.

Notes:

• This section summarizes general biological knowledge of SRPX-like proteins; it is not a claim of performance for this item. Users should validate SRPX expression in their model system and titrate siRNA conditions accordingly.
• No clinical or diagnostic use is implied. For research use only (as stated in Product Data).

Buffer Applications

While this product is not a classical buffering agent, buffers are critical for siRNA handling and performance. The following are general, literature-based practices (not item-specific specifications):

• Stock preparation:
  • Preferred: Nuclease-free water or 1× TE (10 mM Tris-HCl, pH 7.5–8.0; 0.1–1 mM EDTA).
  • Rationale: Tris provides pH stability; EDTA chelates divalent cations that can catalyze RNA hydrolysis.
• Working solutions for transfection:
  • Prepare siRNA–reagent complexes in serum-free, antibiotic-free medium (e.g., Opti-MEM or manufacturer-recommended buffer) to promote efficient complexation; then add to complete medium.
• Electroporation:
  • Use the instrument-specific electroporation buffer; many systems provide low-conductivity buffers validated for RNA delivery.
• RNase control:
  • Use DEPC-treated or commercially certified RNase-free water. Dedicate buffer aliquots and tools to RNA work to avoid contamination.
• Storage buffer considerations:
  • For long-term frozen storage, TE at low EDTA (0.1–0.3 mM) can improve stability; avoid high-salt buffers that may crystallize at −20°C and during freeze–thaw.

Recipes (typical literature values):

• 10× TE: 100 mM Tris-HCl, 10 mM EDTA, pH 7.5–8.0. Dilute to 1× for use.

Always validate buffer compatibility with your chosen transfection method and cell model. No item-specific buffer formulation is provided; refer to the CoA/Spec Sheet if available.

Green Alternatives

This product is an siRNA oligonucleotide set used in biological assays. Conventional “green solvent” substitution considerations are not directly applicable.

• Sustainability considerations (general):
  • Use aqueous buffers (nuclease-free water/TE) instead of organic solvents.
  • Minimize single-use plastics by planning dilutions and aliquots carefully to reduce freeze–thaw waste.
  • Choose low-toxicity transfection reagents and follow institutional waste segregation to limit solvent and biowaste streams.

No direct greener chemical alternative is pertinent for an siRNA reagent; environmental impact is better managed through experimental design and waste minimization.

Pharmaceutical Uses

This product is supplied strictly for research use only. No clinical, diagnostic, or therapeutic applications are supported or implied.

Context (general information, not item-specific):

• In pharmaceutical development, siRNA technologies may be used during discovery research to validate targets and pathways in cell-based assays. Such usage informs mechanism studies but is distinct from any clinical formulation work.
• Oligonucleotides used for human administration require dedicated GMP manufacturing, extensive analytical characterization (identity, purity, residual solvents, endotoxin), and regulatory documentation. This product is not manufactured or qualified for such uses.

Researchers should restrict use to in vitro or non-regulated exploratory studies per institutional policies and local regulations.

Physical Properties

As an siRNA set (mixture of short RNA duplexes), conventional small-molecule property fields are generally not applicable. Where values would be item-specific, none are provided in the Product Data.

• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular Weight: Not specified for this item; refer to CoA/Spec Sheet. (Note: A 21-mer RNA duplex would typically be ~13–14 kDa per duplex; literature, general value, not item-specific.)
• Molecular Formula: Not specified for this item; refer to CoA/Spec Sheet.
• Melting temperature (Tm): Not specified for this item; refer to CoA/Spec Sheet. (Literature: siRNA duplex Tm commonly >60°C depending on GC content and composition.)
• Solubility: Readily soluble in nuclease-free water or TE buffer (10 mM Tris, 0.1–1 mM EDTA), literature guidance; item-specific solvent recommendations are not provided.
• pKa, logP, density, refractive index, UV cutoff: Not applicable/not defined for oligonucleotide mixtures; not specified for this item.
• Absorbance: Literature guidance—RNA quantification typically at A260 (1 A260 ≈ 40 µg/mL for single-stranded RNA; duplex factors vary). No item-specific extinction coefficients are provided.

For precise concentration, Tm, and any stabilizer/lyoprotectant content, please consult the item’s CoA/Spec Sheet.

Quality and Grades

• Grade/Purity: Not specified for this item; refer to CoA/Spec Sheet.

Context for siRNA quality (general, literature/practice):

• Oligonucleotide synthesis quality is typically described by coupling efficiency and final purification method (e.g., desalting, cartridge/OPC, HPLC, PAGE). Higher-grade purifications (HPLC/PAGE) reduce truncated sequences and improve performance while minimizing off-target effects from impurities.
• Identity confirmation may include analytical HPLC and mass spectrometry traces for each duplex. For pooled sets, vendors may provide per-duplex QC or a composite certificate.
• Residual salts/solvents, endotoxin/bioburden, and RNase: For cell-based gene-silencing, low endotoxin and RNase-free handling are important. Item-specific limits are not provided here; see CoA.
• Set A designation usually indicates a curated collection of multiple, non-overlapping siRNA duplexes to the same gene, enabling rapid screening for the most effective silencer(s) before follow-up with individual duplexes (general practice; not item-specific).
• Stabilizers/Modifications (e.g., 2′-OMe, 2′-F, phosphorothioate, overhang composition) impact nuclease resistance and on-target efficacy. No modification details are provided for this item; consult the CoA if applicable.

If your application (e.g., primary cells, in vivo modeling, or high-content screens) requires specific specs (purity, endotoxin, sterility), request and review the CoA/Spec Sheet prior to use.

Reaction and Applications

This section is framed for chemical reactions, but for siRNA reagents, the relevant “applications” are RNAi-based gene silencing workflows.

Key research applications (literature/practice):

• Transient knockdown of SRPX mRNA in human cell lines to study SRPX-dependent pathways (e.g., adhesion, extracellular interactions) and to generate loss-of-function phenotypes for mechanistic studies.
• Assay development: Validate SRPX contribution in reporter assays, proteomics readouts, or phenotypic screens before committing to CRISPR-based knockouts.
• Pathway mapping: Combine with overexpression/rescue constructs to confirm on-target effects.

Experimental tips:

• Run a duplex screen: Test each duplex in the set individually and as a pool to identify the most potent sequence(s) while monitoring off-target signatures.
• Include controls: Non-targeting siRNA, positive control siRNA (to a housekeeping gene with measurable phenotype), and if needed, siGLO/fluorescent uptake controls.
• Optimize cell line–specific conditions: Transfection reagent, cell confluence (often 50–70%), serum conditions, and dose-response (commonly 5–50 nM siRNA; literature ranges) to balance efficacy and viability.
• Verification: Quantify mRNA reduction by RT-qPCR (24–48 h) and protein knockdown by Western blot/ELISA (48–96 h), normalizing to appropriate housekeeping references.

Manufacturer Applications: Not provided; content above expands on standard siRNA use cases and should be adapted to your system.

Reaction Conditions

Classical reaction conditions (solvent, temperature, catalysts) are not applicable to siRNA reagents. For practical laboratory use, consider the following general, literature-based conditions for cellular delivery and knockdown (not item-specific specifications):

• Transfection (lipid/polymer-based):
  • siRNA dose: commonly 5–50 nM final concentration in culture; optimize to minimize cytotoxicity.
  • Cell confluence at transfection: typically 50–70% for adherent lines.
  • Complexation: incubate siRNA with transfection reagent in serum-free medium for 5–20 min at room temperature per reagent protocol.
  • Incubation: add complexes to cells and maintain under standard culture conditions (37°C, 5% CO2).
  • Readouts: mRNA (24–48 h), protein (48–96 h) post-transfection.
• Electroporation/Nucleofection:
  • Follow system-specific programs and buffers; siRNA mass per million cells and pulse parameters vary by instrument and cell type.
• Controls: Non-targeting siRNA, mock (reagent only), and positive control siRNA are essential for interpretation.

These are general guidance ranges derived from common RNAi protocols. Optimize empirically for your specific cell model and delivery reagent. No validated, product-specific reaction/assay conditions are provided in the Product Data.

Safety and Handling

• GHS classification, signal word, pictograms, H-statements: Not specified for this item; refer to the current SDS for authoritative hazard information.
• General hazard profile (literature/practice): Synthetic siRNA oligonucleotides are typically regarded as low hazard in laboratory use; however, they should be handled as laboratory chemicals with appropriate precautions.

Best practices for safe handling of siRNA reagents:

• Use RNase-free technique: Wear clean, powder-free gloves; use RNase-free tubes, tips, and buffers; avoid touching tube rims; change gloves frequently.
• Engineering controls: Work in a clean area; for lyophilized powders, open gently to avoid aerosolization. If preparing transfection mixtures, handle within a biosafety cabinet (as required by your biosafety protocol) to reduce aerosol exposure and contamination risk.
• PPE: Lab coat, safety glasses, and gloves are recommended. Avoid inhalation of dust/aerosols and contact with skin/eyes.
• Incompatibilities: Avoid RNase contamination, strong oxidizers, and nuclease-rich biological materials. Store away from moisture and heat.
• First aid (overview; defer to SDS): If inhaled, move to fresh air. If on skin or in eyes, rinse with water for several minutes. If ingested, rinse mouth and seek medical attention as appropriate.
• Waste: Dispose of unused siRNA and transfection mixtures according to institutional biosafety and chemical waste procedures.

Always consult the product SDS and institutional EHS guidance for definitive safety requirements.

Solvent Selection

This product is an siRNA set rather than a small-molecule solute. Traditional organic solvent selection is not typically applicable.

• Practical diluents (literature guidance):

  • Nuclease-free water for stock solutions (commonly 10–50 µM working stocks).
  • TE buffer (10 mM Tris-HCl, pH 7.5–8.0; 0.1–1 mM EDTA) to enhance stability during long-term frozen storage by chelating divalent cations that catalyze RNA degradation.
  • For transfection, dilute in serum-free, antibiotic-free medium for complexation with lipid/polymer reagents, followed by addition to complete medium per reagent instructions.

• Not recommended: Routine dissolution in organic solvents (e.g., DMSO, DMF) is generally avoided for RNA duplexes due to solubility and stability concerns, unless specifically validated.

No item-specific solvent or vehicle recommendations are provided; consult the CoA/Spec Sheet and your transfection reagent protocol for precise guidance.

Storage and Reconstitution

• Storage Conditions (item-specific from Product Data): Store at −20°C.
• Shipping (item-specific): Shipped in ice chest + ice pads.
• Research Use: For research use only.

Reconstitution and handling (general, literature-based guidance; not item-specific specifications):

• Upon receipt, briefly centrifuge to collect material. If lyophilized, reconstitute in RNase-free water or 1× TE (10 mM Tris-HCl, pH 7.5–8.0; 0.1–1 mM EDTA) to a convenient stock concentration (e.g., 10–50 µM). If supplied in solution, verify concentration on the CoA before dilution.
• Prepare single-use aliquots to avoid repeated freeze–thaw cycles.
• Storage after reconstitution: Common practice is −20°C to −80°C for months; avoid frost-free freezers. For frequent use, keep a working aliquot at 4°C for up to one week (monitor performance). Item-specific stability data are not provided; consult the CoA/Spec Sheet.
• Avoid RNase contamination: Use RNase-free consumables; change gloves frequently; keep tubes closed when not in use.
• Thawing: Thaw on ice, mix gently (do not vortex vigorously), and briefly spin down before use.

Any stabilizers, exact concentration, and shelf-life are not specified for this item; refer to CoA/Spec Sheet for definitive instructions.

Structure and Identity

This product is a pre-designed small interfering RNA (siRNA) set targeting the human SRPX gene (Sushi Repeat Containing Protein, X-linked). Each component is a short double-stranded RNA duplex engineered for RNA interference–mediated knockdown of SRPX mRNA.

• Item type: Synthetic siRNA duplexes (Set A) targeting Homo sapiens SRPX
• Composition: Multiple distinct siRNA duplexes directed to non-overlapping regions of SRPX transcript(s) to enhance knockdown robustness and minimize off-target reliance (general practice for siRNA sets; not item-specific).
• Functional groups/structure: Short (~19–23 bp) A/U/G/C ribonucleotide duplexes with characteristic 3′ overhangs (typically 2 nt) and phosphodiester backbones; sense and antisense strands form a Watson–Crick paired helix recognized by RISC (general siRNA structural features; not item-specific).
• Chemical identifiers (item-specific):
  • CAS: Not specified for this item; refer to CoA/Spec Sheet.
  • InChIKey: Not applicable to mixtures/oligo sets; not specified for this item.
  • SMILES: Not applicable to polymeric/oligo mixtures; not specified for this item.
  • Molecular Formula: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular Weight: Not specified for this item; refer to CoA/Spec Sheet.

2D description in words (general): Each duplex consists of a 5′-phosphorylated guide (antisense) strand complementary to SRPX mRNA and a passenger (sense) strand. Duplex termini may include 3′ overhangs (e.g., dTdT) to improve RISC loading and stability (literature). Any chemical stabilizations or modifications (e.g., 2′-OMe, phosphorothioate) are not specified for this item; consult the CoA if present.

Synthetic Utility

Not applicable in the classical organic synthesis sense. This is an siRNA tool reagent rather than a building block or small molecule.

Practical utility in experimental design (general):

• Facilitates loss-of-function studies for SRPX by RNAi, enabling causal assessment in signaling and extracellular matrix pathways.
• Serves as a screening tool to identify effective duplexes before focusing on a single sequence for detailed studies or rescue experiments.
• Can be integrated into high-content screens or transcriptomic workflows to map SRPX-dependent gene networks.

For chemical synthesis or transformation workflows, please refer to other catalog categories better suited to small-molecule or building-block chemistry.

Target Specificity

• Target: SRPX (Sushi Repeat Containing Protein, X-linked)
• Species: Human (Homo sapiens)
• Modality: Pre-designed siRNA Set A (multiple duplexes targeting non-overlapping regions; general description, not item-specific count)
• Intended effect: Sequence-specific knockdown of SRPX mRNA via RNA interference (RISC-mediated cleavage/silencing).
• Cross-reactivity: Not specified for this item; refer to CoA/Spec Sheet. Sequence homology analysis to non-target transcripts should be performed in silico for your organism/model.
• Validation: Not specified for this item; users should validate knockdown by RT-qPCR and/or immunoblotting in their system.

Note: No sequence information, modification patterns, or off-target assessment data are provided in the Product Data. For detailed target region(s), seed sequences, or alignment reports, consult the CoA/Spec Sheet if available or contact technical support.